Brief: Biocorrx Completes Final Subject Enrollment In Phase I Clinical Trial Of Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
13/10/2022 13:39
Oct 13 (Reuters) - BioCorRx Inc BICX.PK :
* BIOCORRX COMPLETES FINAL SUBJECT ENROLLMENT IN PHASE I
CLINICAL
TRIAL OF BICX104, AN IMPLANTABLE NALTREXONE PELLET FOR THE
TREATMENT OF OPIOID USE DISORDER
Source text for Eikon: ID:nGNX3VxWnC
Further company coverage: BICX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biocorrx
See all newsBrief: BioCorRx Submits Fast Track Application To FDA For Bicx104, An Implantable Biodegradable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: Biocorrx Announces Completion Of Treatment Phase Of Study Subjects And Preliminary Safety Data From Phase I Clinical Trial Of Bicx104
Brief: BioCorRx Partners With Government Plus To Expand Its Beat Addiction Recovery Program In The United States
Brief: Biocorrx Completes Final Subject Enrollment In Phase I Clinical Trial Of Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: BioCorRx Begins Recruitment for Clinical Trial of BICX104